Efficacy and Safety on the Use of Bisphosphonates in Paediatrics


The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: December 31, 2018


  • Other: No intervention, observational study
    • No intervention, observational study

Arms, Groups and Cohorts

  • Pamidronate therapy
  • Zoledronate therapy

Clinical Trial Outcome Measures

Primary Measures

  • fracture rates
    • Time Frame: 2 years
    • (numbers)
  • bone mineral density
    • Time Frame: 2 years
    • (Z-score)
  • pain frequency
    • Time Frame: 2 years
    • (never, occasional, regular)

Participating in This Clinical Trial

Inclusion Criteria

  • be under 18 years of age – have been treated by intravenous bisphosphonates for primary or secondary osteoporosis Exclusion Criteria:

  • be over 18 years of age

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire de Nīmes
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.